News und Analysen
3 Growth Stocks for Farsighted Investors
"I skate to where the puck is going to be, not to where it has been." - Wayne GretzkyWe Fools love this Gretzky quote because it is so applicable to investing. After all, when buying stocks, your....
Here's Why Tahoe Resources Stock Fell as Much as 22.1% Today
Shares of precious metals miner Tahoe Resources (NYSE: TAHO) dropped over 22% today after the company provided an update about its Escobal mine in Guatemala. As of 2:27 p.m. EDT, the stock was....
Here's the Simple Issue I Still Have With Valeant Pharmaceuticals (and Why You Shouldn't Buy)
Over the past two years, only a small handful of publicly traded companies have the distinction of losing more than 90% of their value. Drugmaker Valeant Pharmaceuticals (NYSE: VRX) finds itself....
Better Buy: Franco-Nevada Corporation vs. IAMGOLD Corp.
Many gold stocks are on the radars of individual investors today, especially as painful business decisions are now seemingly behind some of the best companies. Many gold miners also have new....
3 Key Takeaways From Ritchie Bros. Auctioneers' Strong Second Quarter
Ritchie Bros. Auctioneers (NYSE: RBA) had a strong 2016, driven in large part by the surge in demand for equipment tied to the oil and gas markets. Its stock jumped 46% during the year. 2017, however
Shares of Pan American Silver Spike on Earnings Surprise
Shares of Pan American Silver (NASDAQ: PAAS) are up 12.5% as of 12:00 p.m. EDT today after the company posted better-than-expected revenue and earnings for the second quarter.Pan American reported
5 Reasons Valeant's Situation Could Get Worse
Valeant Pharmaceuticals (NYSE: VRX) announced some good news in its second-quarter update on Tuesday. The drugmaker now expects to cut its debt by $5 billion sooner than its previous target of
Earnings Hangover Sacks Valeant Pharmaceuticals' Stock, Sending Shares Down 10%
Shares of embattled drugmaker Valeant Pharmaceuticals (NYSE: VRX) are pulling an about-face after initially moving higher following the release of its second-quarter earnings results before the
Finally! 3 Figures From Valeant's Second-Quarter Report That Demonstrate Improvement
If you've ever played the board game Chutes and Ladders and landed on space 87, which throws the player back 63 spaces, you might have some idea of what it's been like to be a Valeant Pharmaceuticals
Earnings Beat Sends Shares of Ritchie Bros. Auctioneers Nearly 9% Higher
Shares of Ritchie Bros. Auctioneers (NYSE: RBA), a global auction company offering solutions for buying and selling used heavy equipment, trucks, and other massive industrial assets, are rising 9%
Here's Why Valeant Pharmaceuticals Intl. Inc. Surged as Much as 10%
Shares of Valeant Pharmaceuticals (NYSE: VRX), the embattled drugmaker that's traditionally grown through acquisitions and price hikes over the years, surged as much as 10% during Tuesday's trading
Valeant Pharmaceuticals' Debt Reduction Overshadows Drop in Revenue
One major question Valeant Pharmaceuticals (NYSE: VRX) had to answer when the company reported its second-quarter results was this: How significant was the impact of loss of exclusivity for....
Valeant Pharmaceuticals' Debt Reduction Overshadows Drop in Revenue
One major question Valeant Pharmaceuticals (NYSE: VRX) had to answer when the company reported its second-quarter results was this: How significant was the impact of loss of exclusivity for several of
The 2 Most Important Figures in Valeant's Second-Quarter Report (and Neither Is EPS or Debt)
Earnings season remains in full swing, and tomorrow morning, one of the most popular and embattled drugmakers in the entire market is set to reports its second-quarter results.Valeant Pharmaceuticals
3 Things You'll Want to Watch in Valeant Pharmaceuticals' Q2 Results
Good news from Valeant Pharmaceuticals (NYSE: VRX)?That's what investors got the last time the drugmaker announced its quarterly results. Valeant posted a profit in the first quarter. Its balance
It's Time for Investors to Get Over the Biggest Misconception About Valeant Pharmaceuticals
Nearly two years ago to the day, Valeant Pharmaceuticals (NYSE: VRX) would hit almost $264 a share in intraday trading and support a roughly $90 billion market valuation. The embattled drugmaker has
Roundtable: 3 Stocks We Can't Wait to Buy on Sale
The data doesn't lie: High-quality stocks tend to rise in value over the long term. However, that doesn't mean they go up in a straight line. We're investors, and that inherently means we want to buy
Why Yamana Gold Inc. Shareholders Have Something to Worry About
Yamana Gold Inc. (NYSE: AUY) sees better days ahead for its investors. With the upcoming completion of its Cerro Moro project in Argentina, the company has clearly visible gold and silver production
Better Buy: Valeant Pharmaceuticals International, Inc. vs. Gilead Sciences
When it comes to the high-flying healthcare sector, there aren't many bargains to be had. President Trump's recent change of heart regarding the possibility of hard caps on high-priced prescription
Valeant Just Showed Why Its Share Price Has Deservedly Fallen by 93% Since August 2015
Most drug companies have been relatively unstoppable over the past couple of years, partly because of the optimism surrounding a stock market that keeps hitting new all-time highs, and partly due to
IAMGold – Bärenstarke Aktie mit Enttäuschungspotenzial!
Die letzten Wochen waren nicht einfach für alle Goldminenaktienanteilseigner. Der Goldpreis und der HUI schwangen sich von einer Divergenz zur nächsten. Per Tendenz geht es jedoch seit den....
Valeant: Plus 19 % an einem Tag! Was ist da los?
Lieber Leser,
die Aktie des strauchelnden und hoch verschuldeten Pharma-Unternehmens Valeant Pharmaceuticals Inc. konnte am Dienstag im Zuge der Veröffentlichung der Quartalszahlen per Q1 2017....
Valeant Pharma: Starke Zahlen bringen die Kursexplosion! Neue Chance?
Nach einem Aufbäumen im Februar ging es mit Valeant Pharma seit März weiter nach unten und das Tief wurde im April bei 7,926 Euro notiert.
Die Gegenwehr erfolgte sofort und am Dienstag brachten....
Kinross Gold – Geschäftsverlauf zuletzt nur mäßig überzeugend!
Lieber Leser,
obwohl der Goldpreis am Dienstagvormittag nachgab, legten die Kurse der Aktie von Kinross Gold im europäischen Handel knapp 2% zu. Offenbar bewertet der Markt die kurz zuvor....
Ballard Power: Klingt geheimnisvoller als es ist!
Liebe Leser,
Ballard Power konnte offenbar einen lukrativen Auftrag von einem führenden Automobilhersteller ergattern. Ballard verzichtete jedoch darauf, den Namen des Unternehmens sowie den....